IRP1-independent alterations of cardiac iron metabolism in doxorubicin-treated mice
10.1007/s00109-006-0068-y
Crossref journal-article
Springer Science and Business Media LLC
Journal of Molecular Medicine (297)
Bibliography

Corna, G., Galy, B., Hentze, M. W., & Cairo, G. (2006). IRP1-independent alterations of cardiac iron metabolism in doxorubicin-treated mice. Journal of Molecular Medicine, 84(7), 551–560.

Authors 4
  1. Gianfranca Corna (first)
  2. Bruno Galy (additional)
  3. Matthias W. Hentze (additional)
  4. Gaetano Cairo (additional)
References 43 Referenced 23
  1. Singal PK, Iliskovic N (1998) Doxorubicin-induced cardiomyopathy. N Engl J Med 339:900–905 (10.1056/NEJM199809243391307) / N Engl J Med by PK Singal (1998)
  2. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56:185–229 (10.1124/pr.56.2.6) / Pharmacol Rev by G Minotti (2004)
  3. Dorr RT (1996) Cytoprotective agents for anthracyclines. Semin Oncol 23:23–34 / Semin Oncol by RT Dorr (1996)
  4. Hershko C, Link G, Tzahor M, Kaltwasser JP, Athias P, Grynberg A, Pinson A (1993) Anthracycline toxicity is potentiated by iron and inhibited by deferoxamine: studies in rat heart cells in culture. J Lab Clin Med 122:245–251 / J Lab Clin Med by C Hershko (1993)
  5. Hershko C, Link G, Tzahor M, Pinson A (1993) The role of iron and iron chelators in anthracycline cardiotoxicity. Leuk Lymphoma 11:207–214 (10.3109/10428199309086997) / Leuk Lymphoma by C Hershko (1993)
  6. Link G, Tirosh R, Pinson A, Hershko C (1996) Role of iron in the potentiation of anthracycline cardiotoxicity: identification of heart cell mitochondria as a major site of iron-anthracycline interaction. J Lab Clin Med 127:272–278 (10.1016/S0022-2143(96)90095-5) / J Lab Clin Med by G Link (1996)
  7. Miranda CJ, Makui H, Soares RJ, Bilodeau M, Mui J, Vali H, Bertrand R, Andrews NC, Santos MM (2003) Hfe deficiency increases susceptibility to cardiotoxicity and exacerbates changes in iron metabolism induced by doxorubicin. Blood 102:2574–2580 (10.1182/blood-2003-03-0869) / Blood by CJ Miranda (2003)
  8. Hentze MW, Muckenthaler MU, Andrews NC (2004) Balancing acts: molecular control of mammalian iron metabolism. Cell 117:285–297 (10.1016/S0092-8674(04)00343-5) / Cell by MW Hentze (2004)
  9. Smith SR, Cooperman S, Lavaute T, Tresser N, Ghosh M, Meyron-Holtz E, Land W, Ollivierre H, Jortner B, Switzer R third, Messing A, Rouault TA (2004) Severity of neurodegeneration correlates with compromise of iron metabolism in mice with iron regulatory protein deficiencies. Ann N Y Acad Sci 1012:65–83 (10.1196/annals.1306.006) / Ann N Y Acad Sci by SR Smith (2004)
  10. Galy B, Ferring D, Benesova M, Benes V, Hentze MW (2004) Targeted mutagenesis of the murine IRP1 and IRP2 genes reveals context-dependent RNA processing differences in vivo. RNA 10:1019–1025 (10.1261/rna.7220704) / RNA by B Galy (2004)
  11. Galy B, Ferring D, Minana B, Bell O, Janser HG, Muckenthaler M, Schumann K, Hentze MW (2005) Altered body iron distribution and microcytosis in mice deficient for iron regulatory protein 2 (IRP2). Blood 106:2580–2589 (10.1182/blood-2005-04-1365) / Blood by B Galy (2005)
  12. Galy B, Ferring D, Hentze MW (2005) Generation of conditional alleles of the murine iron regulatory protein (IRP)-1 and -2 genes. Genesis 43:181–188 (10.1002/gene.20169) / Genesis by B Galy (2005)
  13. Cooperman SS, Meyron-Holtz EG, Olivierre-Wilson H, Ghosh MC, McConnell JP, Rouault TA (2005) Microcytic anemia, erythropoietic protoporphyria, and neurodegeneration in mice with targeted deletion of iron-regulatory protein 2. Blood 106:1084–1091 (10.1182/blood-2004-12-4703) / Blood by SS Cooperman (2005)
  14. Meyron-Holtz EG, Ghosh MC, Iwai K, LaVaute T, Brazzolotto X, Berger UV, Land W, Ollivierre-Wilson H, Grinberg A, Love P, Rouault TA (2004) Genetic ablations of iron regulatory proteins 1 and 2 reveal why iron regulatory protein 2 dominates iron homeostasis. EMBO J 23:386–395 (10.1038/sj.emboj.7600041) / EMBO J by EG Meyron-Holtz (2004)
  15. Kotamraju S, Chitambar CR, Kalivendi SV, Joseph J, Kalyanaraman B (2002) Transferrin receptor-dependent iron uptake is responsible for doxorubicin-mediated apoptosis in endothelial cells: role of oxidant-induced iron signaling in apoptosis. J Biol Chem 277:17179–17187 (10.1074/jbc.M111604200) / J Biol Chem by S Kotamraju (2002)
  16. Kwok JC, Richardson DR (2002) Unexpected anthracycline-mediated alterations in iron-regulatory protein-RNA-binding activity: the iron and copper complexes of anthracyclines decrease RNA-binding activity. Mol Pharmacol 62:888–900 (10.1124/mol.62.4.888) / Mol Pharmacol by JC Kwok (2002)
  17. Minotti G, Ronchi R, Salvatorelli E, Menna P, Cairo G (2001) Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy. Cancer Res 61:8422–8428 / Cancer Res by G Minotti (2001)
  18. Corna G, Santambrogio P, Minotti G, Cairo G (2004) Doxorubicin paradoxically protects cardiomyocytes against iron-mediated toxicity: role of reactive oxygen species and ferritin. J Biol Chem 279:13738–13745 (10.1074/jbc.M310106200) / J Biol Chem by G Corna (2004)
  19. Minotti G, Recalcati S, Mordente A, Liberi G, Calafiore AM, Mancuso C, Preziosi P, Cairo G (1998) The secondary alcohol metabolite of doxorubicin irreversibly inactivates aconitase/iron regulatory protein-1 in cytosolic fractions from human myocardium. FASEB J 12:541–552 (10.1096/fasebj.12.7.541) / FASEB J by G Minotti (1998)
  20. Brazzolotto X, Andriollo M, Guiraud P, Favier A, Moulis JM (2003) Interactions between doxorubicin and the human iron regulatory system. Biochim Biophys Acta 1593:209–218 (10.1016/S0167-4889(02)00391-9) / Biochim Biophys Acta by X Brazzolotto (2003)
  21. Kalin MF, Zumoff B (1990) Sex hormones and coronary disease: a review of the clinical studies. Steroids 55:330–352 (10.1016/0039-128X(90)90058-J) / Steroids by MF Kalin (1990)
  22. Douglas PS, Katz SE, Weinberg EO, Chen MH, Bishop SP, Lorell BH (1998) Hypertrophic remodeling: gender differences in the early response to left ventricular pressure overload. J Am Coll Cardiol 32:1118–1125 (10.1016/S0735-1097(98)00347-7) / J Am Coll Cardiol by PS Douglas (1998)
  23. Santambrogio P, Cozzi A, Levi S, Rovida E, Magni F, Albertini A, Arosio P (2000) Functional and immunological analysis of recombinant mouse H- and L-ferritins from Escherichia coli. Protein Expr Purif 19:212–218 (10.1006/prep.2000.1212) / Protein Expr Purif by P Santambrogio (2000)
  24. Mullner EW, Neupert B, Kuhn LC (1989) A specific mRNA binding factor regulates the iron-dependent stability of cytoplasmic transferrin receptor mRNA. Cell 58:373–382 (10.1016/0092-8674(89)90851-9) / Cell by EW Mullner (1989)
  25. Cairo G, Tacchini L, Pogliaghi G, Anzon E, Tomasi A, Bernelli-Zazzera A (1995) Induction of ferritin synthesis by oxidative stress. Transcriptional and post-transcriptional regulation by expansion of the “free” iron pool. J Biol Chem 270:700–703 (10.1074/jbc.270.2.700) / J Biol Chem by G Cairo (1995)
  26. Leibold EA, Aziz N, Brown AJ, Munro HN (1984) Conservation in rat liver of light and heavy subunit sequences of mammalian ferritin. Presence of unique octopeptide in the light subunit. J Biol Chem 259:4327–4334 (10.1016/S0021-9258(17)43049-3) / J Biol Chem by EA Leibold (1984)
  27. Murray MT, White K, Munro HN (1987) Conservation of ferritin heavy subunit gene structure: implications for the regulation of ferritin gene expression. Proc Natl Acad Sci USA 84:7438–7442 (10.1073/pnas.84.21.7438) / Proc Natl Acad Sci USA by MT Murray (1987)
  28. Ohkawa H, Ohishi N, Yagi K (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351–358 (10.1016/0003-2697(79)90738-3) / Anal Biochem by H Ohkawa (1979)
  29. Bowie AG, Moynagh PN, O’Neill LA (1997) Lipid peroxidation is involved in the activation of NF-kappaB by tumor necrosis factor but not interleukin-1 in the human endothelial cell line ECV304. Lack of involvement of H2O2 in NF-kappaB activation by either cytokine in both primary and transformed endothelial cells. J Biol Chem 272:25941–25950 (10.1074/jbc.272.41.25941) / J Biol Chem by AG Bowie (1997)
  30. Childs AC, Phaneuf SL, Dirks AJ, Phillips T, Leeuwenburgh C (2002) Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2:Bax ratio. Cancer Res 62:4592–4598 / Cancer Res by AC Childs (2002)
  31. Shioji K, Kishimoto C, Nakamura H, Masutani H, Yuan Z, Oka S, Yodoi J (2002) Overexpression of thioredoxin-1 in transgenic mice attenuates adriamycin-induced cardiotoxicity. Circulation 106:1403–1409 (10.1161/01.CIR.0000027817.55925.B4) / Circulation by K Shioji (2002)
  32. Yamamoto M, Yang G, Hong C, Liu J, Holle E, Yu X, Wagner T, Vatner SF, Sadoshima J (2003) Inhibition of endogenous thioredoxin in the heart increases oxidative stress and cardiac hypertrophy. J Clin Invest 112:1395–1406 (10.1172/JCI200317700) / J Clin Invest by M Yamamoto (2003)
  33. Kuhn M, Voss M, Mitko D, Stypmann J, Schmid C, Kawaguchi N, Grabellus F, Baba HA (2004) Left ventricular assist device support reverses altered cardiac expression and function of natriuretic peptides and receptors in end-stage heart failure. Cardiovasc Res 64:308–314 (10.1016/j.cardiores.2004.07.004) / Cardiovasc Res by M Kuhn (2004)
  34. Xu X, Persson HL, Richardson DR (2005) Molecular pharmacology of the interaction of anthracyclines with iron. Mol Pharmacol 68:261–271 (10.1124/mol.105.013383) / Mol Pharmacol by X Xu (2005)
  35. Kudoh K, Ramanna M, Ravatn R, Elkahloun AG, Bittner ML, Meltzer PS, Trent JM, Dalton WS, Chin KV (2000) Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. Cancer Res 60:4161–4166 / Cancer Res by K Kudoh (2000)
  36. Torti FM, Torti SV (2002) Regulation of ferritin genes and protein. Blood 99:3505–3516 (10.1182/blood.V99.10.3505) / Blood by FM Torti (2002)
  37. Harrison PM, Arosio P (1996) The ferritins: molecular properties, iron storage function and cellular regulation. Biochim Biophys Acta 1275:161–203 (10.1016/0005-2728(96)00022-9) / Biochim Biophys Acta by PM Harrison (1996)
  38. Cozzi A, Corsi B, Levi S, Santambrogio P, Biasiotto G, Arosio P (2004) Analysis of the biologic functions of H- and L-ferritins in HeLa cells by transfection with siRNAs and cDNAs: evidence for a proliferative role of L-ferritin. Blood 103:2377–2383 (10.1182/blood-2003-06-1842) / Blood by A Cozzi (2004)
  39. LaVaute T, Smith S, Cooperman S, Iwai K, Land W, Meyron-Holtz E, Drake SK, Miller G, Abu-Asab M, Tsokos M, Switzer R 3rd, Grinberg A, Love P, Tresser N, Rouault TA (2001) Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice. Nat Genet 27:209–214 (10.1038/84859) / Nat Genet by T LaVaute (2001)
  40. Sagnella GA (2001) Measurement and importance of plasma brain natriuretic peptide and related peptides. Ann Clin Biochem 38:83–93 (10.1258/0004563011900317) / Ann Clin Biochem by GA Sagnella (2001)
  41. McDonagh TA, Robb SD, Murdoch DR, Morton JJ, Ford I, Morrison CE, Tunstall-Pedoe H, McMurray JJ, Dargie HJ (1998) Biochemical detection of left-ventricular systolic dysfunction. Lancet 351:9–13 (10.1016/S0140-6736(97)03034-1) / Lancet by TA McDonagh (1998)
  42. Recalcati S, Alberghini A, Campanella A, Gianelli U, De Camilli E, Conte D, Cairo G (2006) Iron regulatory proteins 1 and 2 in human monocytes, macrophages and duodenum: expression and regulation in hereditary hemochromatosis and iron deficiency. Haematologica 91:303–310 / Haematologica by S Recalcati (2006)
  43. Wingert RA, Galloway JL, Barut B, Foott H, Fraenkel P, Axe JL, Weber GJ, Dooley K, Davidson AJ, Schmid B, Paw BH, Shaw GC, Kingsley P, Palis J, Schubert H, Chen O, Kaplan J, Zon LI (2005) Deficiency of glutaredoxin 5 reveals Fe-S clusters are required for vertebrate haem synthesis. Nature 436:1035–1039 (10.1038/nature03887) / Nature by RA Wingert (2005)
Dates
Type When
Created 19 years, 2 months ago (June 12, 2006, 11:17 a.m.)
Deposited 4 years, 1 month ago (July 28, 2021, 3:28 a.m.)
Indexed 2 months, 3 weeks ago (June 2, 2025, 9:50 p.m.)
Issued 19 years, 2 months ago (June 13, 2006)
Published 19 years, 2 months ago (June 13, 2006)
Published Online 19 years, 2 months ago (June 13, 2006)
Published Print 19 years, 1 month ago (July 1, 2006)
Funders 0

None

@article{Corna_2006, title={IRP1-independent alterations of cardiac iron metabolism in doxorubicin-treated mice}, volume={84}, ISSN={1432-1440}, url={http://dx.doi.org/10.1007/s00109-006-0068-y}, DOI={10.1007/s00109-006-0068-y}, number={7}, journal={Journal of Molecular Medicine}, publisher={Springer Science and Business Media LLC}, author={Corna, Gianfranca and Galy, Bruno and Hentze, Matthias W. and Cairo, Gaetano}, year={2006}, month=jun, pages={551–560} }